Literature DB >> 27829581

Enhanced Intestinal Absorption of Cholesterol along with Increased Chylomicron Remnants for De novo Progression of Coronary Stenosis.

Daisaku Masuda1, Shizuya Yamashita.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2016        PMID： 27829581      PMCID： PMC5305672          DOI： 10.5551/jat.ED065

Source DB:  PubMed          Journal:  J Atheroscler Thromb        ISSN： 1340-3478            Impact factor:   4.928


× No keyword cloud information.
  8 in total

1.  Establishment of chemiluminescence enzyme immunoassay for apolipoprotein B-48 and its clinical applications for evaluation of impaired chylomicron remnant metabolism.

Authors:  Hiroyuki Hanada; Satomi Mugii; Manabu Okubo; Ikuhiro Maeda; Kazuya Kuwayama; Yoh Hidaka; Rika Kitazume-Taneike; Taiji Yamashita; Ryota Kawase; Hajime Nakaoka; Miwako Inagaki; Miyako Yuasa-Kawase; Kazuhiro Nakatani; Kazumi Tsubakio-Yamamoto; Daisaku Masuda; Tohru Ohama; Akifumi Matsuyama; Masato Ishigami; Makoto Nishida; Issei Komuro; Shizuya Yamashita
Journal:  Clin Chim Acta       Date:  2011-09-19       Impact factor: 3.786

2.  Aggressive lipid-lowering therapy compared with angioplasty in stable coronary artery disease. Atorvastatin versus Revascularization Treatment Investigators.

Authors:  B Pitt; D Waters; W V Brown; A J van Boven; L Schwartz; L M Title; D Eisenberg; L Shurzinske; L S McCormick
Journal:  N Engl J Med       Date:  1999-07-08       Impact factor: 91.245

3.  Serum apolipoprotein B-48 levels are correlated with carotid intima-media thickness in subjects with normal serum triglyceride levels.

Authors:  Kazuhiro Nakatani; Taizo Sugimoto; Daisaku Masuda; Rieko Okano; Tomoko Oya; Yasumasa Monden; Taiji Yamashita; Ryota Kawase; Hajime Nakaoka; Miwako Inagaki; Miyako Yuasa-Kawase; Kazumi Tsubakio-Yamamoto; Tohru Ohama; Makoto Nishida; Masato Ishigami; Issei Komuro; Shizuya Yamashita
Journal:  Atherosclerosis       Date:  2011-05-18       Impact factor: 5.162

4.  Fasting serum concentration of apolipoprotein B48 represents residual risks in patients with new-onset and chronic coronary artery disease.

Authors:  Kenta Mori; Tatsuro Ishida; Tomoyuki Yasuda; Tomoko Monguchi; Maki Sasaki; Kensuke Kondo; Minoru Hasokawa; Hideto Nakajima; Yoko Haraguchi; Li Sun; Masakazu Shinohara; Ryuji Toh; Kunihiro Nishimura; Ken-ichi Hirata
Journal:  Clin Chim Acta       Date:  2013-02-18       Impact factor: 3.786

5.  Alterations in cholesterol absorption/synthesis markers characterize Framingham offspring study participants with CHD.

Authors:  Nirupa R Matthan; Michael Pencina; Jane M LaRocque; Paul F Jacques; Ralph B D'Agostino; Ernst J Schaefer; Alice H Lichtenstein
Journal:  J Lipid Res       Date:  2009-05-12       Impact factor: 5.922

6.  Correlation of fasting serum apolipoprotein B-48 with coronary artery disease prevalence.

Authors:  Daisaku Masuda; Taizo Sugimoto; Ken-Ichi Tsujii; Miwako Inagaki; Kazuhiro Nakatani; Miyako Yuasa-Kawase; Kazumi Tsubakio-Yamamoto; Tohru Ohama; Makoto Nishida; Masato Ishigami; Toshiharu Kawamoto; Akifumi Matsuyama; Naohiko Sakai; Issei Komuro; Shizuya Yamashita
Journal:  Eur J Clin Invest       Date:  2012-05-15       Impact factor: 4.686

Review 7.  Remnant lipoproteins as strong key particles to atherogenesis.

Authors:  Yoshio Fujioka; Yuichi Ishikawa
Journal:  J Atheroscler Thromb       Date:  2009-06-25       Impact factor: 4.928

8.  Enhanced Impact of Cholesterol Absorption Marker on New Atherosclerotic Lesion Progression After Coronary Intervention During Statin Therapy.

Authors:  Kenta Mori; Tatsuro Ishida; Shigeyasu Tsuda; Toshihiko Oshita; Masakazu Shinohara; Tetsuya Hara; Yasuhiro Irino; Ryuji Toh; Ken-Ichi Hirata
Journal:  J Atheroscler Thromb       Date:  2016-08-04       Impact factor: 4.928
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.